Arthritis drug xeljanz XR under Real-World watch in korea
NCT ID NCT04876781
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study tracks the safety and effectiveness of the arthritis drug Xeljanz XR in about 200 adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Participants take the drug as prescribed by their doctor, and researchers record any side effects and changes in disease activity over about four years. The goal is to see how well the drug works and how safe it is in everyday medical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE ANKYLOSING SPONDYLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.